Go Pro
→ Universal basic income is not impossible. It exist (kind of) (From Freedom Financial) (Ad)tc pixel Free SPRO Stock Alerts

Spero Therapeutics (SPRO) Competitors

Spero Therapeutics logo
$1.16 -0.11 (-8.66%)
Closing price 07/23/2026 04:00 PM Eastern
Extended Trading
$1.10 -0.06 (-5.60%)
As of 07:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SPRO vs. PRLD, LYEL, FHTX, ELDN, and NMRA

Should you buy Spero Therapeutics stock or one of its competitors? MarketBeat compares Spero Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spero Therapeutics include Prelude Therapeutics (PRLD), Lyell Immunopharma (LYEL), Foghorn Therapeutics (FHTX), Eledon Pharmaceuticals (ELDN), and Neumora Therapeutics (NMRA). These companies are all part of the "pharmaceutical products" industry.

How does Spero Therapeutics compare to Prelude Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, Prelude Therapeutics had 2 more articles in the media than Spero Therapeutics. MarketBeat recorded 2 mentions for Prelude Therapeutics and 0 mentions for Spero Therapeutics. Prelude Therapeutics' average media sentiment score of 1.11 beat Spero Therapeutics' score of 0.00 indicating that Prelude Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Spero Therapeutics Neutral
Prelude Therapeutics Positive

Spero Therapeutics has higher revenue and earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spero Therapeutics$66.80M1.01$8.57M$0.244.83
Prelude Therapeutics$12.14M25.78-$99.50M-$1.00N/A

Spero Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Spero Therapeutics has a net margin of 24.90% compared to Prelude Therapeutics' net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Prelude Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Spero Therapeutics24.90% 35.58% 24.95%
Prelude Therapeutics N/A -118.24%-66.12%

Prelude Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 95.08%. Given Prelude Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Prelude Therapeutics is more favorable than Spero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spero Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Prelude Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Spero Therapeutics and Prelude Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Spero Therapeutics compare to Lyell Immunopharma?

Lyell Immunopharma (NASDAQ:LYEL) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

Spero Therapeutics has a net margin of 24.90% compared to Lyell Immunopharma's net margin of -794,858.12%. Spero Therapeutics' return on equity of 35.58% beat Lyell Immunopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Lyell Immunopharma-794,858.12% -85.71% -66.41%
Spero Therapeutics 24.90%35.58%24.95%

Lyell Immunopharma has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by company insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Lyell Immunopharma had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 1 mentions for Lyell Immunopharma and 0 mentions for Spero Therapeutics. Lyell Immunopharma's average media sentiment score of 0.83 beat Spero Therapeutics' score of 0.00 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company Overall Sentiment
Lyell Immunopharma Positive
Spero Therapeutics Neutral

Spero Therapeutics has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lyell Immunopharma$40K7,827.75-$274.45M-$13.80N/A
Spero Therapeutics$66.80M1.01$8.57M$0.244.83

Lyell Immunopharma presently has a consensus target price of $43.20, suggesting a potential upside of 238.03%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, research analysts plainly believe Lyell Immunopharma is more favorable than Spero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lyell Immunopharma
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75
Spero Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

Lyell Immunopharma beats Spero Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Spero Therapeutics compare to Foghorn Therapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Foghorn Therapeutics presently has a consensus price target of $11.43, indicating a potential upside of 125.42%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Foghorn Therapeutics is more favorable than Spero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Foghorn Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88
Spero Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Spero Therapeutics has a net margin of 24.90% compared to Foghorn Therapeutics' net margin of -266.88%. Spero Therapeutics' return on equity of 35.58% beat Foghorn Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Foghorn Therapeutics-266.88% N/A -35.38%
Spero Therapeutics 24.90%35.58%24.95%

61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 9.0% of Foghorn Therapeutics shares are owned by company insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Spero Therapeutics has higher revenue and earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Foghorn Therapeutics$30.91M9.63-$74.28M-$1.16N/A
Spero Therapeutics$66.80M1.01$8.57M$0.244.83

Foghorn Therapeutics has a beta of 2.86, meaning that its stock price is 186% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

In the previous week, Foghorn Therapeutics' average media sentiment score of 0.00 equaled Spero Therapeutics'average media sentiment score.

Company Overall Sentiment
Foghorn Therapeutics Neutral
Spero Therapeutics Neutral

Summary

Foghorn Therapeutics beats Spero Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Spero Therapeutics compare to Eledon Pharmaceuticals?

Spero Therapeutics (NASDAQ:SPRO) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Spero Therapeutics has a net margin of 24.90% compared to Eledon Pharmaceuticals' net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Eledon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Spero Therapeutics24.90% 35.58% 24.95%
Eledon Pharmaceuticals N/A -116.97%-41.91%

Eledon Pharmaceuticals has a consensus price target of $10.25, suggesting a potential upside of 174.06%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Spero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spero Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Eledon Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Eledon Pharmaceuticals had 4 more articles in the media than Spero Therapeutics. MarketBeat recorded 4 mentions for Eledon Pharmaceuticals and 0 mentions for Spero Therapeutics. Eledon Pharmaceuticals' average media sentiment score of 0.33 beat Spero Therapeutics' score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Spero Therapeutics Neutral
Eledon Pharmaceuticals Neutral

Spero Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by company insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Spero Therapeutics has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spero Therapeutics$66.80M1.01$8.57M$0.244.83
Eledon PharmaceuticalsN/AN/A-$45.62M-$0.77N/A

Summary

Spero Therapeutics beats Eledon Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Spero Therapeutics compare to Neumora Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Neumora Therapeutics presently has a consensus price target of $6.57, suggesting a potential upside of 321.25%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Neumora Therapeutics is more favorable than Spero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neumora Therapeutics
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.60
Spero Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Spero Therapeutics has a net margin of 24.90% compared to Neumora Therapeutics' net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Neumora Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neumora TherapeuticsN/A -181.70% -119.15%
Spero Therapeutics 24.90%35.58%24.95%

In the previous week, Neumora Therapeutics had 2 more articles in the media than Spero Therapeutics. MarketBeat recorded 2 mentions for Neumora Therapeutics and 0 mentions for Spero Therapeutics. Neumora Therapeutics' average media sentiment score of 0.67 beat Spero Therapeutics' score of 0.00 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Neumora Therapeutics Positive
Spero Therapeutics Neutral

Spero Therapeutics has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neumora TherapeuticsN/AN/A-$236.93M-$1.33N/A
Spero Therapeutics$66.80M1.01$8.57M$0.244.83

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by company insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Neumora Therapeutics has a beta of 2.74, indicating that its share price is 174% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Summary

Neumora Therapeutics beats Spero Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Spero Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPRO vs. The Competition

Export
MetricSpero TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$73.54M$3.64B$6.81B$12.60B
Dividend YieldN/A2.19%2.68%9.43%
P/E Ratio4.8321.5926.8323.83
Price / Sales1.01303.98519.0191.18
Price / Cash8.35156.7450.4359.93
Price / Book1.108.0110.026.10
Net Income$8.57M$23.81M$3.60B$331.84M
7 Day Performance-26.58%-1.95%-1.80%-1.15%
1 Month Performance-44.76%-1.78%-1.09%-2.74%
1 Year Performance-50.64%34.82%19.74%14.97%

Spero Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPRO
Spero Therapeutics
0.6146 of 5 stars		$1.16
-8.7%		N/A-51.3%$73.54M$66.80M4.83150
PRLD
Prelude Therapeutics
2.9513 of 5 stars		$4.04
-0.6%		$7.67
+90.0%		+331.9%$321.35M$12.14MN/A120
LYEL
Lyell Immunopharma
3.8728 of 5 stars		$12.97
+0.4%		$43.00
+231.6%		+16.3%$317.67M$40KN/A270
FHTX
Foghorn Therapeutics
1.9126 of 5 stars		$5.24
+0.9%		$11.43
+118.1%		-21.6%$307.05M$30.91MN/A120
ELDN
Eledon Pharmaceuticals
1.9689 of 5 stars		$3.97
+2.7%		$9.67
+143.8%		-1.8%$306.06MN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SPRO) was last updated on 7/24/2026 by MarketBeat.com Staff.
From Our Partners
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Elon's next move will be bigger than the IPO – and it could happen any day now
Hedge fund legend Larry Benedict - who delivered a 279% return on cash in 2025 and went on a 20-year winning s...
Brownstone Research | Sponsoredtc pixel
Two paths to universal income. One already exists today.
Robert Kiyosaki, author of Rich Dad Poor Dad, says there are two paths to Universal Basic Income - wait for El...
Freedom Financial | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Solar lost. Wind lost. One won.
Washington cut subsidies for solar, wind, and EVs - but one energy source had its tax credits fully preserved ...
Behind the Markets | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The $40 billion "side project" Elon buried inside SpaceX
Elon Musk has been quietly building a $40 billion project inside SpaceX — housed in a converted refrigerator f...
The Oxford Club | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel